ArticleFrontiers in endocrinology2024
Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Global burden and temporal trend of thyroid cancer associated with high BMI from 1990 to 2021.PloS one · 2026Article
- Preparedness for generative AI adoption among Chinese cancer survivors: a multi-center cross-sectional survey study.Frontiers in public health · 2026Article
- Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021: an analysis derived from the Global Burden of Disease Study 2021.Frontiers in endocrinology · 2025Article
- Global and China burden and trend prediction of thyroid cancer attributed to high BMI from 1990 to 2021.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer (TC) is a prevalent malignant tumor of the endocrine system in China. Current research primarily focuses on clinical diagnosis and treatment as well as underlying mechanisms, lacking epidemiological studies on the burden of the disease in China and worldwide. Methods: The Global Burden of Disease Study 2021 was utilized to assess the incidence, prevalence, death, and disability-adjusted life years of TC in China and worldwide from 1990 to 2021 using the Joinpoint and R software. Results: From 1990 to 2021, the incidence and prevalence rates of TC in China have been consistently rising, and their growth rates are far higher than the global average. In China, TC usually occurs in patients aged 50-59, and the crude death rate generally increases with age. The burden of death among females has gradually declined, while that among males has continued to increase and surpassed females at the beginning of the 21st century. The burden of TC is heavy among middle-aged and elderly populations and the younger populations is also rapidly rising. The increased number of TC is mainly attributed to epidemiological changes, while the increase of deaths in China is primarily due to aging and population. Additionally, we predict that the age-standardized incidence rate of TC in China will continue to grow slowly over the next decade, while the age-standardized death rate will gradually decline among females and stabilize among males. Conclusion: It is imperative to avoid over-screening and over-treatments for TC. Meanwhile, we should also avoid missing aggressive types of TC that may have an impact on overall survival. Additionally, understanding the mechanisms of metastasis and improving clinical treatments should be prioritized for further investigation. TC remains a significant public health challenge in China, necessitating a careful balance of the cost-benefit ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.